Abstract:
We read with interest the results of the recent Infectious Diseases Society of America’s (IDSA’s) Emerging Infections Network (EIN) survey regarding the management of Staphylococcus aureus bacteremia (SAB). We conducted a similar survey of infectious diseases (ID) physicians and microbiologists in Australia and New Zealand through the Ozbug e-mail discussion forum during January to March 2017. We surveyed clinicians about specific management decisions for 2 cases of SAB. We also asked about clinical equipoise and priorities for future research. We found significant variation in practice, particularly for patients with a severe disease phenotype and antibiotic-resistant profile, and that there is clinician equipoise for studies to address controversies in SAB management.
A Survey of Infectious Diseases and Microbiology Clinicians in Australia and New Zealand About the Management of Staphylococcus aureus Bacteremia
Significant variation in practice, particularly for patients with a severe disease phenotype and antibiotic-resistant profile